June 22, 2022
2 min watch
Save
VIDEO: Novel agent shows promise in thrombocytopenia myelofibrosis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In a video interview, Aaron Thomas Gerds, MD, MS, discussed the efficacy and safety of momelotinib in a subset of patients with thrombocytopenic myelofibrosis from the MOMENTUM study, which was presented at ASCO Annual Meeting.
“We saw that even when patients were thrombocytopenic, there was still an advantage for momelotinib over danazol,” Gerds, of Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, told Healio.
Published by:
Sources/Disclosures
Collapse
Source:
Gerds AT, et al. Abstract 7061. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Disclosures:
Gerds reports consulting or advising for AbbVie, Bristol-Myers Squibb, Constellation Pharmaceuticals, CTI BioPharma Corp, Novartis, PharmaEssentia and Sierra Oncology.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.